Global technology provider Trialbee has announced a partnership with Datavant to power patient-centric clinical trial recruitment and engagement.
Under the partnership, Trialbee will power its clinical trial recruitment and patient engagement solutions using Datavant’s open data ecosystem.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
De-identified data will be analysed to determine the characteristics of patients who may be eligible and motivated to participate in a clinical trial.
Trialbee CEO Lollo Eriksson said: “We are solving for the investigator fatigue and demotivation caused by unguided mega screening for patient recruitment and the low results it produces.
“This partnership with Datavant will significantly expand our access to real-world data (RWD) and ability to choose the information assets that are most relevant for any given trial.
“This unique collaboration will improve specificity and drive the right patients to clinical trials, improving efficiency and time to last patient enrolled.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataTrialbee is a global patient recruitment and engagement company with integrated patient sourcing using RWD from claims data, electronic health records data, as well as digital outreach to the general public.
Datavant CEO Travis May said: “Trialbee is tackling a critical problem with a fresh perspective: how to more effectively recruit patients to clinical trials and keep them engaged once they are enrolled.
“We are thrilled for the partnership to support their access to real-world data sources across Datavant’s open data ecosystem.”
In October last year, Trialbee partnered with health research network TriNetX for data-driven digital solutions to accelerate patient-centric clinical trials. Trialbee offers software to cut trial recruitment timelines and improve the patient engagement experience.
